<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32085981</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Transforming growth factor-&#x3b2; plasma levels and its role in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>109632</StartPage><MedlinePgn>109632</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2020.109632</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(20)30026-8</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscle paralysis. Respiratory complications are the main cause of death in ALS. For this reason, initial respiratory status and its decline over disease progression are strong independent predictors of survival. Riluzole, a glutamatergic neurotransmission inhibitor, is the only drug that has shown to extend survival. Therefore, both novel molecular biomarkers and treatment strategies are needed. Transforming growth factor-&#x3b2; (TGF-&#x3b2;) family cytokines are important regulators of cell fate affecting both neurogenesis and neurodegeneration. Several studies demonstrate that TGF-&#x3b2; signalling protects neurons from glutamate-mediated excitotoxicity, a recognized mechanism underlying the pathogenesis of various neurodegenerative disorders such as ALS. Recent studies report dysregulations of the TGF-&#x3b2; system as a common feature of neurodegenerative disorders. The upregulation of this system has been linked with ALS progression. We have quantified TGF-&#x3b2;1, TGF-&#x3b2;2 and TGF-&#x3b2;3 serum levels in 23 ALS patients and 12 healthy controls, our preliminary results support the hypothesis that TGF-&#x3b2;3 levels can be a marker disease severity ALS. Further results are necessary to confirm this hypothesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duque</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gromicho</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pronto-Laborinho</LastName><ForeName>Ana Catarina</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Department of Neurosciences and Mental Health, Centro Hospitalar Universit&#xe1;rio de Lisboa-Norte, Lisbon, Portugal. Electronic address: mamedemg@mail.telepac.pt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>76057-06-2</RegistryNumber><NameOfSubstance UI="D015291">Transforming Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="Y">Transforming Growth Factor beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015291" MajorTopicYN="N">Transforming Growth Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Predictive value</Keyword><Keyword MajorTopicYN="N">Progression</Keyword><Keyword MajorTopicYN="N">Transforming growth factor-&#x3b2; plasma levels</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32085981</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2020.109632</ArticleId><ArticleId IdType="pii">S0306-9877(20)30026-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>